Tranexamic acid

Chemical formula: C₈H₁₅NO₂  Molecular mass: 157.21 g/mol  PubChem compound: 5526

Therapeutic indications

Tranexamic acid is indicated for:

Fibrinolysis and menorrhagia or metrorrhagia

Population group: women, only adults (18 - 65 years old)

Haemorrhage caused by general or local fibrinolysis such as menorrhagia and metrorrhagia.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention and treatment of haemorrhages due to general or local fibrinolysis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Prevention and treatment of haemorrhages due to general or local fibrinolysis in children from one year.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention and treatment of haemorrhages due to general or local fibrinolysis

Population group: only adults (18 years old or older)

Prevention and treatment of haemorrhages due to general or local fibrinolysis in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Haemorrhage due to fibrinolytic agent

Population group: only adults (18 years old or older)

Management of haemorrhage due to the administration of a fibrinolytic agent.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Haemorrhage due to fibrinolytic agent

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Management of haemorrhage due to the administration of a fibrinolytic agent.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tranexamic acid is contraindicated in the following cases:

Acute venous or arterial thrombosis

Thrombosis

Fibrinolytic conditions following consumption coagulopathy

Fibrinolytic bleeding syndrome

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

History of convulsions

Seizure

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2021: CYKLOKAPRON Solution for injection
Summary of Product Characteristics (SPC) 2019: TRANEXAMIC ACID Tranexamic acid containing medicinal products
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈